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S U M M A R Y
This work reports the occurrence of New Delhi metallo-beta-lactamase 1 (NDM-1) in metallo-beta-
lactamase-producing Pseudomonas aeruginosa in Egypt for the ﬁrst time, and the presence of more than
one blaMBL gene in carbapenem-resistant P. aeruginosa.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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New Delhi metallo-beta-lactamase 1 (NDM-1) has received
wide attention because of the extreme resistance it confers, its
presence in many common pathogens, its rapid spread to multiple
continents, and local nosocomial spread in some areas. Most early
reports of infections were in individuals who had received medical
care in the Indian subcontinent.1 The ﬁrst variant of NDM-1 –
NDM-2 – was detected in Acinetobacter baumannii from Egypt.2 The
acquisition of NDM-1 by two clinical isolates of metallo-beta-
lactamase (MBL)-producing Pseudomonas aeruginosa in Egypt and
the association of blaVIM-2 with the blaNDM-1 in these two isolates is
reported herein.* Corresponding author. Tel.: +20 201111112472.
E-mail address: mai_zafer@hotmail.com (M.M. Zafer).
http://dx.doi.org/10.1016/j.ijid.2014.07.008
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).2. Case report
The two P. aeruginosa isolates were recovered from hospitalized
inpatients admitted to Kasr Al Aini Hospital, Cairo University,
Egypt during March 2012. The ﬁrst isolate was from a wound
specimen obtained from a young man (23 years old) who had
suffered 30% burns and was hospitalized in the surgical ward; he
spent 10 days in the hospital. The second P. aeruginosa isolate was
obtained from a sputum specimen recovered from a 74-year-old
man who had a history of underlying malignancy (glioma) and who
had undergone a brain tumor excision. He was hospitalized in the
intensive care unit; he spent 22 days in the hospital. Both patients
were alive after the hospitalization period.
The isolates were conﬁrmed by VITEK 2 (bioMe´rieux, Marcy
l’Etoile, France) and the minimum inhibitory concentrations
(MICs) of selected antimicrobials were determined by Etest (AB
Biodisk, Solna, Sweden). Both strains were resistant to imipenem
and meropenem. The resistance patterns of both isolates are
illustrated in Table 1.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Minimum inhibitory concentrations (Etest, mg/ml) for Pseudomonas aeruginosa clinical isolates
Antibiotic
FEP TZP CAZ CAZ/CLA CIP AMK GEN IPM CTX
CLSI resistance break point 32 128/4 128/2 32 4 64 4 16 32
Wound 64 256 256 256 32 256 256 32 256
Sputum 24 256 256 192 32 256 12 32 256
FEP, cefepime; TZP, piperacillin/tazobactam; CAZ, ceftazidime; CAZ/CLA, ceftazidime/clavulanic acid; CIP, ciproﬂoxacin; AMK, amikacin; GEN, gentamicin; IPM, imipenem;
CTX, cefotaxime.
M.M. Zafer et al. / International Journal of Infectious Diseases 29 (2014) 80–81 81Both isolates were positive for MBL production by combined
disk test. PCRs with primers speciﬁc for blaVIM-2 (AAAGTTATGCCG-
CACTCACC and TGCAACTTCATGTTATGCCG)3 and blaNDM-1 (CACCT-
CATGTTTGAATTCGCC and CTCTGTCACATCGAAATCGC)2 revealed
ampliﬁcation of a 984-bp fragment corresponding to blaNDM-1
and a fragment of 865 bp corresponding to the blaVIM-2 gene. PCRs
with primers speciﬁc for blaIMP (50-GAAGGYGTTTATGTTCATAC-30
and 50-GTAMGTTTCAAGAGTGATGC-30), blaSPM (50-CTGCTTGGATT-
CATGGGCGC-30 and 50-CCTTTTCCGCGACCTTGATC-30), blaGIM (50-
TCGACACACCTTGGTCTG-30 and 50-AACTTCCAACTTTGCCAT-30), and
blaSIM (50-TACAAGGGATTCGGCATCC-30 and 50-TAATGGCCTGTTCC-
CATG-30) genes were negative.3,4
Typing by multilocus sequence typing (MLST) of the recognized
chromosomal markers (seven housekeeping genes) acsA, aroE,
guaA, mutL, nuoD, ppsA, and trpE (http://pubmlst.org/paeruginosa/)
showed similarity in which sequence type (ST) 233, which is a part
of the internationally dominant clonal cluster CC233, was detected
in the two isolates.
3. Discussion
NDM-1-producers are now alarmingly on the increase world-
wide and pose a potential risk for therapeutic failure with the
empirical treatments currently in place.5 The ﬁrst identiﬁcation of a
blaNDM gene in a clinical isolate originated from Egypt, with no
obvious link to the Indian subcontinent.2 Prior to the detection of
the NDM-1-positive P. aeruginosa strains, neither of the patients
in our study had traveled to the Indian subcontinent or any European
country. Thus, either these patients experienced cross-transmission
with NDM-1 cases that were travel-associated (but not reported),
or inappropriate and non-prescription antibiotic use might have
been the cause of the development of high antimicrobial resistance.The presence of blaVIM-2 together with blaNDM-1 in the two
P. aeruginosa isolates reported in this study indicates the dissemi-
nation of blaMBL-carrying organisms in Egypt.
Typing by MLST of the two isolates revealed both to belong to
ST233, indicating that health care-acquired transfer of P. aerugi-
nosa could occur; an increased risk of cross-transmission and
high antimicrobial pressure might have favored clonal spread.
In addition, patients who have the potential to facilitate the
dissemination of multidrug-resistant organisms between hospitals
may subsequently serve as important reservoirs and transmission
sources, stressing the importance of hand hygiene compliance
and patient precautions.
In conclusion, this ﬁnding of NDM-1-producing P. aeruginosa
and the presence of more than one blaMBL gene in carbapenem-
resistant P. aeruginosa highlights the emerging therapeutic
challenge. The implementation of strict antimicrobial policies
and infection control programs may help to prevent the rapid
dissemination of these organisms.
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